Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Kynmobi (APL-130277) in Parkinson's Disease OFF Episodes
NCT02542696Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Aug 2015
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of apomorphine in Parkinson's disease (PD), sponsored by Sumitomo Pharma America. Primary endpoint: Evaluation of Safety and Tolerability Data Collected, Based on Number of Participants With Adverse Events in the LTS Phase at 3 years. Started Aug 2015; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02542696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02542696.